West Pharmaceutical Services Stock Alpha and Beta Analysis
| WST Stock | USD 328.17 8.31 2.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as West Pharmaceutical Services. It also helps investors analyze the systematic and unsystematic risks associated with investing in West Pharmaceutical over a specified time horizon. Remember, high West Pharmaceutical's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to West Pharmaceutical's market risk premium analysis include:
Beta 0.89 | Alpha (0.13) | Risk 1.49 | Sharpe Ratio (0.20) | Expected Return (0.30) |
West Pharmaceutical Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
West |
West Pharmaceutical Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. West Pharmaceutical market risk premium is the additional return an investor will receive from holding West Pharmaceutical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in West Pharmaceutical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate West Pharmaceutical's performance over market.| α | -0.13 | β | 0.89 |
West Pharmaceutical expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of West Pharmaceutical's Buy-and-hold return. Our buy-and-hold chart shows how West Pharmaceutical performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.West Pharmaceutical Market Price Analysis
Market price analysis indicators help investors to evaluate how West Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading West Pharmaceutical shares will generate the highest return on investment. By understating and applying West Pharmaceutical stock market price indicators, traders can identify West Pharmaceutical position entry and exit signals to maximize returns.
West Pharmaceutical Return and Market Media
The median price of West Pharmaceutical for the period between Thu, Mar 14, 2024 and Wed, Jun 12, 2024 is 368.35 with a coefficient of variation of 7.02. The daily time series for the period is distributed with a sample standard deviation of 25.64, arithmetic mean of 365.2, and mean deviation of 21.45. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 64132 shares by Eric Green of West Pharmaceutical at 359.8511 subject to Rule 16b-3 | 03/25/2024 |
2 | What Makes West Pharmaceutical Services an Attractive Bet | 04/01/2024 |
3 | Acquisition by Thomas Hofmann of 564 shares of West Pharmaceutical subject to Rule 16b-3 | 04/23/2024 |
4 | West Pharmaceutical Services Inc. Q1 2024 Earnings Adjusted EPS Rises Amidst Sales Decline | 04/25/2024 |
5 | West Pharmaceutical Services, Inc. Q1 2024 Earnings Call Transcript | 04/30/2024 |
| West Pharmaceutical dividend paid on 1st of May 2024 | 05/01/2024 |
6 | West Pharmaceutical Services, Inc. Receives 435.20 Consensus Target Price from Analysts - Defense World | 05/03/2024 |
7 | Acquisition by Reiss-clark Cindy of 1588 shares of West Pharmaceutical at 274.29 subject to Rule 16b-3 | 05/09/2024 |
8 | Massachusetts Financial Services Co. MA Has 233.50 Million Stock Holdings in West Pharmaceutical Services, Inc ... - MarketBeat | 05/14/2024 |
9 | Estimating The Fair Value Of West Pharmaceutical Services, Inc. | 05/21/2024 |
10 | West Introduces Daikyo Crystal Zenith Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy | 05/29/2024 |
11 | West Pharmaceutical Services, Inc. The Best Dividend Aristocrat Stock According to Analysts | 06/06/2024 |
12 | Industry Comparison Evaluating Agilent Technologies Against Competitors In Life Sciences Tools Services Industry | 06/11/2024 |
About West Pharmaceutical Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including West or other stocks. Alpha measures the amount that position in West Pharmaceutical has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.001464 | 0.00309 | 0.002179 | 0.00207 | Price To Sales Ratio | 12.32 | 6.07 | 8.87 | 9.31 |
West Pharmaceutical Upcoming Company Events
As portrayed in its financial statements, the presentation of West Pharmaceutical's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, West Pharmaceutical's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of West Pharmaceutical's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of West Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of West Pharmaceutical's management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with West Pharmaceutical
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.